


TUMOR LIQUID BIOPSY SYMPOSIUM 2017

SEPTEMBER 25TH
Centre de Congrès Prouvé, Nancy, France



TUMOR LIQUID BIOPSY SYMPOSIUM

2017

SEPTEMBER 25TH
Centre de Congrès Prouvé, Nancy, France

ORGANIZING COMMITTEE

Pr Jean-Louis Merlin, Nancy, France
Dr Alexandre Harlé, Nancy, France
Pr Nikolas von Bubnoff, Freiburg, Germany
Dr Florence Schaffner, Strasbourg, France

SCIENTIFIC COMMITTEE / FACULTY

Anna Babayan, Hamburg, Germany
Fay Betsou, Luxembourg
Romain Boidot, Dijon, France
Florian Clatot, Rouen, France
Christine Clavel, Reims, France
Ralph Fritsch, Freiburg, Germany
Anne Gégout-Petit, Nancy, France
Alexandre Harlé, Nancy, France
Jens Höppner, Freiburg, Germany
Katarina Jahn, Basel, Switzerland
Philippe Jonveaux, Nancy, France
Pierre Laurent-Puig, Paris, France
Jean-Louis Merlin, Nancy, France
Irina Nazarenko, Freiburg, Germany
Pierre Oudet, Strasbourg, France
Nick Papadopoulos, Baltimore, USA
Erwan Pencreac'h, Strasbourg, France
Jean-Yves Pierga, Paris, France
Jean-Luc Prétet, Besançon, France
Florence Schaffner, Strasbourg, France
Florian Scherer, Freiburg, Germany
Giulia Siravegna, Torino, Italy
Dana Tsui, New York, USA
Martin van Royen, Rotterdam, The Netherlands
Jean-Michel Vignaud, Nancy, France
Nikolas von Bubnoff, Freiburg, Germany

ACKNOWLEDGEMENTS



ORGANIZATION

Com&Co - Etienne Jarry 
15, Bd Grawitz - 13016 Marseille, France
Tel.: +33 (0)4 91 09 70 53 - Fax: +33 (0)4 96 15 33 08
Email: ejarry@comnco.com - www.comnco.com





MONDAY, SEPTEMBER 25TH, 2017

08.15 Welcoming introduction

08.30 SESSION 1

DIAGNOSTIC, SCREENING, MONITORING

Chairs: Nikolas von Bubnoff (Freiburg, Germany) & Jean-Louis Merlin (Nancy, France)

08.30 ctDNA for cancer detection and management: ready for prime time? *Dana Tsui (New York, USA)*

09.00 CTC and ctDNA in breast cancer: prognosis marker or molecular diagnostic. *Jean-Yves Pierga (Paris, France)*

09.30 Colon and lung cancer role of liquid biopsy. *Pierre Laurent-Puig (Paris, France)*

10.00 Short communications

10.00 Circulating tumor DNA is a predictor for response to treatment in BRAF V600E mutant malignant melanoma. *Jan Braune (Freiburg, Germany)*

10.10 Rapid and clinically relevant detection of the spectrum of ALK fusion and mutations in non-invasive liquid biopsy ctDNA from patients with lung cancer. *Antoinette Lemoine (Villejuif, France)*

10.20 CTCs in patients with esophageal adenocarcinoma at diagnosis, after neoadjuvant treatment and after surgery (ESO-CTC trial). *Jasmina Kuvendjiska (Freiburg, Germany)*

10.30 Coffee break & poster session

11.00 SESSION 2

RESISTANCE TO TREATMENT, CLONAL EVOLUTION

Chairs: Alexandre Harlé (Nancy, France) & Ralph Fritsch (Freiburg, Germany)

11.00 Monitoring clonal evolution and resistance to targeted agents in the blood and other body fluids of cancer patients. *Giulia Siravegna (Torino, Italy)*

11.20 Capturing clonal evolution and tumor heterogeneity in lymphoma by circulating tumor DNA profiling. *Florian Scherer (Freiburg, Germany)*

11.40 ctDNA and breast cancer resistance to endocrine therapy. *Florian Clatot (Rouen, France)*

12.00 Short communications

12.00 Study of spatial and temporal tumor heterogeneity using whole exome sequencing on cfDNA in neuroblastoma. *Mathieu Chicard (Paris, France)*

12.10 Identification of rare mutations and DNA methylation patterns in cell-free DNA and their impact on personalized cancer treatment using multiplexed Enhanced-ice-COLD-PCR. *Jörg Tost (Fontenay-aux-Roses, France)*

12.20 Discussion

12.30 Lunch break & poster session

14.00 SESSION 3

LIQUID BIOPSY ANALYTICS

Chairs: Jean-Michel Vignaud (Nancy, France) & Jens Höppner (Freiburg, Germany)

14.00 Liquid biopsy: CTCs versus circulating nucleic acids. *Anna Babayan (Hamburg, Germany)*

14.30 Modeling ctDNA dynamics for detecting targeted therapy resistance. *Anne Gégout-Petit (Nancy, France)*

14.50 Modelling tumor evolution from single-cell sequencing data. *Katarina Jahn (Basel, Switzerland)*

15.10 Short communications

15.10 Detection of circulating KRAS mutations in patients with pancreatic cancer: a single center experience. *Saskia Hussung (Freiburg, Germany)*

15.20 Establishing barcoding and target capturing for NGS based ctDNA panel sequencing of NSCLC-patients stages I-III. *Silvia Waldeck (Freiburg, Germany)*

15.30 Coffee break & poster session

16.00 SESSION 4

CIRCULATING BIOMARKERS

Chairs: Erwan Pencreac'h (Strasbourg, France) & Irina Nazarenko (Freiburg, Germany)

16.00 The use of extracellular vesicles as prostate cancer biomarker treasure chests. *Martin van Royen (Rotterdam, The Netherlands)*

16.30 Different types of extracellular vesicles and their application in cancer diagnostics. *Irina Nazarenko (Freiburg, Germany)*

16.50 Quality assurance of liquid biopsy in research. *Fay Betsou (Luxembourg)*

17.10 Short communications

17.10 Tumor derived exosomes as potential metastasis biomarker. *Jessica Gobbo (Dijon, France)*

17.20 Diagnostic potential of micro RNAs expression profiles in serum and urine of breast and gynecologic cancer patients. *Andrea Ritter (Freiburg, Germany)*

17.30 KEYNOTE LECTURES

17.30 Detection of cancer in bodily fluids. *Nick Papadopoulos (Baltimore, USA)*

18.00 Liquid biopsy, CTC and circulating nucleic acids: making the buzz or doing the job? *Nikolas von Bubnoff (Freiburg, Germany) & Jean-Louis Merlin (Nancy, France)*

18.15 Short communication & poster prizes

18.30 Concluding remarks

18.50 Meeting closure